文献速递造血干细胞移植与细胞治疗

小鼠慢性移植物抗宿主病蛋白质组学分析发现CCL15为患者新型生物标志物

Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients.
PubMed 文献 · Blood · 2018-01-18

研究对小鼠多器官系统慢性移植物抗宿主病(cGVHD)模型进行全血清蛋白质组学分析,发现4种上调蛋白,其中CCL9阻断可逆转cGVHD表现;人同源蛋白CCL15在211例cGVHD患者血浆中升高并与非复发死亡相关,但在792例患者中第+100天CCL15不能预测随后3个月内cGVHD。

要点

  • 小鼠cGVHD模型血清蛋白质组学发现CRKL、CXCL7、CCL8和CCL9四种上调蛋白。
  • 阻断CCL9可逆转小鼠cGVHD临床表现、组织病理改变和免疫病理特征。
  • CCL15在211例cGVHD患者血浆中升高且与NRM相关,但第+100天水平不能预测3个月内cGVHD。

核心结论

  • 首次证明临床前蛋白质组学筛查可用于发现cGVHD潜在新靶点,并确定CCL15为cGVHD诊断标志物。
  • 这些数据需要前瞻性生物标志物验证研究。

研究设计与样本

  • 对已建立的小鼠多器官系统cGVHD模型进行全血清蛋白质组学分析,并利用既往发表的211例cGVHD患者队列及792例患者队列验证。

主要发现

  • 小鼠cGVHD期间发现4种上调蛋白,包括RAS和JUN激酶激活剂CRKL以及CXCL7、CCL8和CCL9趋化因子。
  • 供体T细胞缺乏CRK/CRKL可阻止cGVHD发生、生发中心反应和巨噬细胞浸润。
  • 抗体阻断CCL8或CXCL7对cGVHD治疗无效,而CCL9阻断可逆转cGVHD临床表现、组织病理改变和免疫病理标志。
  • CCL9高表达主要见于血管平滑肌细胞,且独特见于cGVHD小鼠。
  • 在既往发表的211例cGVHD患者队列中,人同源蛋白CCL15血浆浓度较对照升高并与NRM相关。

局限性

  • 这些数据需要前瞻性生物标志物验证研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Improved diagnostic and treatment methods are needed for chronic graft-versus-host disease (cGVHD), the leading cause of late nonrelapse mortality (NRM) in long-term survivors of allogenic hematopoietic cell transplantation. Validated biomarkers that facilitate disease diagnosis and classification generally are lacking in cGVHD. Here, we conducted whole serum proteomics analysis of a well-established murine multiorgan system cGVHD model. We discovered 4 upregulated proteins during cGVHD that are targetable by genetic ablation or blocking antibodies, including the RAS and JUN kinase activator, CRKL, and CXCL7, CCL8, and CCL9 chemokines. Donor T cells lacking CRK/CRKL prevented the generation of cGVHD, germinal center reactions, and macrophage infiltration seen with wild-type T cells. Whereas antibody blockade of CCL8 or CXCL7 was ineffective in treating cGVHD, CCL9 blockade reversed cGVHD clinical manifestations, histopathological changes, and immunopathological hallmarks. Mechanistically, elevated CCL9 expression was present predominantly in vascular smooth muscle cells and uniquely seen in cGVHD mice. Plasma concentrations of CCL15, the human homolog of mouse CCL9, were elevated in a previously published cohort of 211 cGVHD patients compared with controls and associated with NRM. In a cohort of 792 patients, CCL15 measured at day +100 could not predict cGVHD occurring within the next 3 months with clinically relevant sensitivity/specificity. Our findings demonstrate for the first time the utility of preclinical proteomics screening to identify potential new targets for cGVHD and specifically CCL15 as a diagnosis marker for cGVHD. These data warrant prospective biomarker validation studies.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Du J, Flynn R, Paz K, et al. Murine chronic graft-versus-host disease proteome profiling discovers CCL15 as a novel biomarker in patients. Blood. 2018. PMID: 29348127. doi:10.1182/blood-2017-08-800623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。